公开(公告)号：US11299553B2

公开(公告)日：2022-04-12

申请号：US16199453

申请日：2018-11-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Andrew Nixon ,  Jon A. Kenniston ,  Stephen R. Comeau

IPC: C07K16/40 ,  C12N15/52

Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.

公开(公告)号：US20220106357A1

公开(公告)日：2022-04-07

申请号：US17492256

申请日：2021-10-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Zhorzh Patatanyan ,  Rohit Murthy ,  Yasser Baddour ,  Alexander Zaydenberg

IPC: C07K1/14 ,  C07K14/745 ,  C07K16/00 ,  C07K14/765 ,  C07K14/81 ,  C07K14/755

Abstract: The present invention provides a method of fractionating human plasma, in some embodiments, using the Cohn fractionation procedure. The improvement comprises the use of physiologically active reconstituted spray dried human plasma as the starting material for the fractionation procedure.

公开(公告)号：US20220099670A1

公开(公告)日：2022-03-31

申请号：US17427222

申请日：2021-01-31

Applicant: Kyoto University ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shin KANEKO ,  Shoichi IRIGUCHI ,  Keiko SEKIYA ,  Yoshiaki KASSAI

IPC: G01N33/567 ,  C12N5/00 ,  C12N5/0784 ,  G01N33/50

Abstract: Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.

公开(公告)号：US20220098142A1

公开(公告)日：2022-03-31

申请号：US17267179

申请日：2019-08-08

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoru Matsumoto ,  Yoshimasa Omori ,  Masahiro Mineno ,  Yasuhiro Sawai ,  Nozomu Kakimoto ,  Yusutaka Hoashi

IPC: C07C229/12 ,  C12N15/113 ,  A61K9/51

Abstract: The present invention provides a technique capable of transferring an active ingredient, particularly, a nucleic acid, to a cell with excellent efficiency and a cationic lipid for use in this technique, etc. The cationic lipid of the present invention is a compound represented by the formula (I) or a salt thereof. n1 represents an integer of 2 to 6, n2 represents an integer of 0 to 2, n3 represents an integer of 0 to 2, L represents —C(O)O— or —NHC(O)O—, Ra represents a linear C5-13 alkyl group, a linear C13-17 alkenyl group or a linear C17 alkadienyl group, Rb represents a linear C2-9 alkyl group, Rc represents a hydrogen atom or a linear C2-9 alkyl group, Rd represents a hydrogen atom or a linear C2-9 alkyl group, Re represents a linear C2-9 alkyl group, and Rf represents a linear C2-9 alkyl group.

公开(公告)号：US11236099B2

公开(公告)日：2022-02-01

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki Takami ,  Masaki Seto ,  Shinobu Sasaki ,  Haruhi Ando ,  Masaki Ogino ,  Tomoko Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Yasuhiro Tsukimi ,  Masami Yamada ,  Kenichiro Shimokawa ,  Takeshi Wakabayashi ,  Masataka Murakami ,  Makoto Fushimi ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Tomohiro Ohashi ,  Hideo Suzuki ,  Hironobu Maezaki ,  Ayumu Sato ,  Yasutomi Asano ,  Steve Swann

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20220023207A1

公开(公告)日：2022-01-27

申请号：US17298460

申请日：2019-11-29

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Akitsu HOTTA ,  Naoko ISHIHARA ,  Ryuichi NISHIGAKI ,  Masaki SETO

IPC: A61K9/08 ,  A61K38/46 ,  A61K47/22 ,  A61K47/26 ,  A61K47/24 ,  A61K31/7088 ,  A61K47/18 ,  A61K47/16 ,  A61K47/12 ,  A61K47/10

Abstract: The present invention provides a means excellent in efficiency of introduction of a nucleic acid, a protein, a complex thereof, or the like into cells, in particular a method using a solution for transduction. In the method for transducing a molecule(s) of interest into a cell according to the present invention, comprising a step of contacting the cell with the molecule(s) of interest and a solution for transduction according to the present invention, the solution for transduction contains: at least one of the following (A1) to (A5); and (B) a salt: (A1) a compound represented by formula (I) excluding a predetermined compound, or a salt thereof; (A2) a compound represented by formula (II), or a salt thereof; (A3) a nucleic-acid base or the like, or a salt thereof; (A4) a compound represented by formula (III), or a salt thereof, excluding malic acid; and (A5) at least one selected from the group consisting of creatinine, hydroxyproline, 1,3-butanediol, trientine, D-cellobiose, 1,3-dimethylurea, pantolactone and trimethadione, or a salt thereof.

公开(公告)号：US11230541B2

公开(公告)日：2022-01-25

申请号：US16634402

申请日：2018-07-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC: C07D409/12 ,  C07D401/12 ,  C07D249/18 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20210381006A1

公开(公告)日：2021-12-09

申请号：US17286334

申请日：2019-10-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinobu KUWAE ,  Satoru MATSUMOTO ,  Akira HAYASHI ,  Yoshiaki KASSAI ,  Kazuhide NAKAYAMA

IPC: C12N15/88 ,  A61K35/17 ,  A61K9/127 ,  C07K16/28

Abstract: The present invention provides a method for activating/proliferating T cells, including a step of contacting a cell population containing T cells with a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface, and a method for delivering a nucleic acid into T cells, the methods including a step of contacting a cell population containing T cells simultaneously with (a) a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface and containing a nucleic acid inside, or (b) at least one kind of T cell activating ligand, and a nucleic acid delivery carrier containing a nucleic acid inside and free of a T cell activating ligand added to its surface, a method for producing a medicament containing T cells and the like.

公开(公告)号：US11191813B2

公开(公告)日：2021-12-07

申请号：US16258490

申请日：2019-01-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Kurt Schnecker ,  Eva Haidweger ,  Peter Turecek

IPC: A61K38/16 ,  A61K38/17 ,  A61K38/36 ,  A61K47/12 ,  A61K47/22 ,  A61K47/26 ,  A61K9/08 ,  A61K9/19 ,  A61P43/00 ,  A61P7/04 ,  C07K14/00 ,  A61K47/18

Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.

公开(公告)号：US11186565B2

公开(公告)日：2021-11-30

申请号：US16499432

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Seiji Miwatashi ,  Yasufumi Miyamoto ,  Koji Watanabe ,  Yayoi Nakayama ,  Yuko Hitomi ,  Jumpei Aida ,  Nobuyuki Takakura ,  Hideki Furukawa ,  Naoyoshi Noguchi ,  Yasuhiro Hirata ,  Kazuaki Takami ,  Norihito Tokunaga ,  Tomohiro Okawa ,  Akito Shibuya ,  Shizuo Kasai ,  Toshitake Kobayashi ,  Tsuyoshi Maekawa

IPC: C07D401/12 ,  C07C59/72 ,  C07D211/22 ,  C07D213/64 ,  C07D401/10 ,  C07D401/14 ,  C07D413/10

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.